Evelo Bio Moves Ahead with EDP1815 Mid Stage Trial
Evelo Biosciences Inc. (EVLO) announced that its lead drug candidate EDP1815 will now be a part of TACTIC-E clinical trial. The trial is designed to assess the safety and efficacy of certain experimental therapies in the preventing and treating various complications related to COVID-19.
TACTIC-E is a Phase 2/3 randomized trial and will involve up to 469 patients in each arm. The participants will be the patients suffering from COVID-19 who have identified risk factors for developing severe complications. These will be patients who